DK1270595T3 - Anti-CCR4-antistof og dets fragment - Google Patents
Anti-CCR4-antistof og dets fragmentInfo
- Publication number
- DK1270595T3 DK1270595T3 DK01908280T DK01908280T DK1270595T3 DK 1270595 T3 DK1270595 T3 DK 1270595T3 DK 01908280 T DK01908280 T DK 01908280T DK 01908280 T DK01908280 T DK 01908280T DK 1270595 T3 DK1270595 T3 DK 1270595T3
- Authority
- DK
- Denmark
- Prior art keywords
- ccr4
- antibody
- fragment
- antibody fragment
- recombinant antibody
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000059508 | 2000-03-03 | ||
JP2000401563 | 2000-12-28 | ||
PCT/JP2001/001656 WO2001064754A1 (fr) | 2000-03-03 | 2001-03-02 | Anticorps a recombinaison genique et son fragment |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1270595T3 true DK1270595T3 (da) | 2008-11-10 |
Family
ID=26586785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01908280T DK1270595T3 (da) | 2000-03-03 | 2001-03-02 | Anti-CCR4-antistof og dets fragment |
Country Status (15)
Country | Link |
---|---|
US (4) | US6989145B2 (de) |
EP (2) | EP1270595B1 (de) |
JP (1) | JP3926153B2 (de) |
KR (1) | KR100890873B1 (de) |
CN (1) | CN100455599C (de) |
AT (1) | ATE402192T1 (de) |
AU (2) | AU2001236073B2 (de) |
CA (1) | CA2401491C (de) |
CY (1) | CY1108397T1 (de) |
DE (1) | DE60134962D1 (de) |
DK (1) | DK1270595T3 (de) |
ES (1) | ES2309050T3 (de) |
PT (1) | PT1270595E (de) |
SI (1) | SI1270595T1 (de) |
WO (1) | WO2001064754A1 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2270147T4 (da) * | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
CA2438375C (en) * | 2001-03-06 | 2014-07-15 | Kazuhito Fujiyama | Plant cell having animal-type sugar chain adding function |
US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
ATE420659T1 (de) | 2001-04-26 | 2009-01-15 | Biogen Idec Inc | Criptoblockierende antikörper und deren verwendung |
DE60238503D1 (de) * | 2001-08-31 | 2011-01-13 | Kyowa Hakko Kirin Co Ltd | Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon |
US7541040B2 (en) | 2001-12-04 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Serivces | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
EP1491209A4 (de) * | 2002-02-28 | 2006-05-17 | Kyowa Hakko Kogyo Kk | Mittel für die diagnose und behandlung der interstitiellen pneumonie |
AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
WO2004072646A1 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5) |
AU2004252171B2 (en) | 2003-06-27 | 2011-04-21 | Biogen Ma Inc. | Modified binding molecules comprising connecting peptides |
FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
AU2004277466C1 (en) | 2003-10-01 | 2022-06-23 | Kyowa Kirin Co., Ltd. | Method of stabilizing antibody and stabilized solution-type antibody preparation |
US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
FR2861395B1 (fr) | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
WO2005053741A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬 |
PT2805728T (pt) | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
US20060034841A1 (en) * | 2004-06-07 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of depleting regulatory T cell |
DK1838736T3 (da) | 2005-01-05 | 2013-06-03 | Biogen Idec Inc | Cripto-bindende molekyler |
WO2009001840A1 (ja) * | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | ADCC活性又はCDC活性を有する抗Prominin-1抗体 |
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
JP5552630B2 (ja) * | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
CN102782131B (zh) | 2010-03-02 | 2015-08-05 | 协和发酵麒麟株式会社 | 修饰抗体组合物 |
US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
NZ609493A (en) | 2010-12-16 | 2015-11-27 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
WO2012130831A1 (en) | 2011-03-29 | 2012-10-04 | Roche Glycart Ag | Antibody fc variants |
US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
EP2870973B1 (de) | 2012-07-06 | 2022-08-31 | St. Marianna University School of Medicine | Heilmittel für patienten mit htlv-1-vermittelter myelopathie |
MY183712A (en) | 2012-07-13 | 2021-03-09 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
KR102571391B1 (ko) | 2013-09-13 | 2023-08-29 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
CA3174012A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
US10675349B2 (en) * | 2014-10-06 | 2020-06-09 | Dana-Farber Cancer Institute, Inc. | Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof |
TW201713332A (zh) | 2015-07-14 | 2017-04-16 | 協和醱酵麒麟有限公司 | 包含與抗體組合投予之ido抑制物之腫瘤治療劑 |
WO2017112564A1 (en) | 2015-12-22 | 2017-06-29 | 3M Innovative Properties Company | Stem-well films for sample partitioning |
EP3471753A1 (de) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1- und il-2-zytokine |
US20210113672A1 (en) * | 2016-12-08 | 2021-04-22 | Nantbio, Inc. | Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
BR112020017715A2 (pt) | 2018-03-16 | 2020-12-29 | Zoetis Services Llc | Vacinas de peptídeo contra interleucina-31 |
AU2019234220A1 (en) | 2018-03-16 | 2020-09-10 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
US20210079087A1 (en) * | 2018-03-29 | 2021-03-18 | Remd Biotherapeutics, Inc. | Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a) |
CA3119467A1 (en) | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US160015A (en) * | 1875-02-23 | Improvement in devices for cutting out sheet-metal washers | ||
US187930A (en) * | 1877-02-27 | Improvement in processes of preserving meat | ||
US19341A (en) * | 1858-02-16 | Louis beauche | ||
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
US5914110A (en) | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
JPH0853355A (ja) | 1994-08-12 | 1996-02-27 | Taisho Pharmaceut Co Ltd | Il−5産生抑制剤 |
GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
PL318594A1 (en) | 1995-06-07 | 1997-06-23 | Icos Corp | Chemokine and analogues thereof originating from macrophages |
AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
DE69835441T2 (de) | 1997-11-12 | 2007-08-02 | F. Hoffmann-La Roche Ag | Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten |
US6355244B1 (en) * | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
AU753131B2 (en) | 1998-06-26 | 2002-10-10 | Chugai Seiyaku Kabushiki Kaisha | Remedies for hypercalcemic crisis |
US6245332B1 (en) * | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
EP1050307A1 (de) * | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | CCR4 Antagoniste in Sepsis |
DE60238503D1 (de) | 2001-08-31 | 2011-01-13 | Kyowa Hakko Kirin Co Ltd | Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon |
US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
WO2005053741A1 (ja) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬 |
US20060034841A1 (en) * | 2004-06-07 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of depleting regulatory T cell |
-
2001
- 2001-03-02 CN CNB018059902A patent/CN100455599C/zh not_active Expired - Lifetime
- 2001-03-02 US US09/796,744 patent/US6989145B2/en not_active Expired - Lifetime
- 2001-03-02 AU AU2001236073A patent/AU2001236073B2/en active Active
- 2001-03-02 WO PCT/JP2001/001656 patent/WO2001064754A1/ja active IP Right Grant
- 2001-03-02 EP EP01908280A patent/EP1270595B1/de not_active Expired - Lifetime
- 2001-03-02 CA CA2401491A patent/CA2401491C/en not_active Expired - Lifetime
- 2001-03-02 AU AU3607301A patent/AU3607301A/xx active Pending
- 2001-03-02 EP EP08013028A patent/EP1992644A1/de not_active Withdrawn
- 2001-03-02 SI SI200130859T patent/SI1270595T1/sl unknown
- 2001-03-02 DE DE60134962T patent/DE60134962D1/de not_active Expired - Lifetime
- 2001-03-02 JP JP2001564247A patent/JP3926153B2/ja not_active Expired - Lifetime
- 2001-03-02 KR KR1020027011583A patent/KR100890873B1/ko active IP Right Grant
- 2001-03-02 DK DK01908280T patent/DK1270595T3/da active
- 2001-03-02 PT PT01908280T patent/PT1270595E/pt unknown
- 2001-03-02 ES ES01908280T patent/ES2309050T3/es not_active Expired - Lifetime
- 2001-03-02 AT AT01908280T patent/ATE402192T1/de active
-
2005
- 2005-03-31 US US11/094,718 patent/US7666418B2/en not_active Expired - Fee Related
-
2008
- 2008-10-06 CY CY20081101104T patent/CY1108397T1/el unknown
-
2010
- 2010-01-08 US US12/684,651 patent/US8197814B2/en not_active Expired - Lifetime
-
2012
- 2012-06-08 US US13/492,465 patent/US8632996B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
SI1270595T1 (sl) | 2008-12-31 |
CN1407993A (zh) | 2003-04-02 |
ATE402192T1 (de) | 2008-08-15 |
CY1108397T1 (el) | 2014-02-12 |
WO2001064754A1 (fr) | 2001-09-07 |
AU3607301A (en) | 2001-09-12 |
US7666418B2 (en) | 2010-02-23 |
ES2309050T3 (es) | 2008-12-16 |
US20020098527A1 (en) | 2002-07-25 |
US6989145B2 (en) | 2006-01-24 |
AU2001236073B2 (en) | 2006-10-19 |
US20050187380A1 (en) | 2005-08-25 |
CA2401491C (en) | 2011-07-05 |
CA2401491A1 (en) | 2001-09-07 |
DE60134962D1 (de) | 2008-09-04 |
EP1270595B1 (de) | 2008-07-23 |
KR100890873B1 (ko) | 2009-03-31 |
US8632996B2 (en) | 2014-01-21 |
CN100455599C (zh) | 2009-01-28 |
US20100221178A1 (en) | 2010-09-02 |
EP1992644A1 (de) | 2008-11-19 |
JP3926153B2 (ja) | 2007-06-06 |
PT1270595E (pt) | 2008-09-16 |
KR20020089377A (ko) | 2002-11-29 |
EP1270595A1 (de) | 2003-01-02 |
US8197814B2 (en) | 2012-06-12 |
US20120276090A1 (en) | 2012-11-01 |
EP1270595A4 (de) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1270595T3 (da) | Anti-CCR4-antistof og dets fragment | |
EA200500497A3 (ru) | ЧЕЛОВЕЧЕСКИЕ АНТИ-IFN-γ НЕЙТРАЛИЗУЮЩИЕ АНТИТЕЛА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ ПУТЕЙ IFN-γ | |
TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
MXPA03000103A (es) | Antigenos de streptococcus. | |
HUP0300868A2 (hu) | Ellenanyag-citokin fúzíós fehérje által közvetített immunválaszok fokozása immuncitokin felvételét elősegítő anyagokkal történő kombinált kezeléssel | |
CY1108765T1 (el) | ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2 | |
MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
HK1087018A1 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
DK1854809T3 (da) | Nukleinsyre og tilsvarende protein betegnet 158P1D7, der er anvendelig i behandling og påvisning af blærecancer og andre cancere | |
IL144265A0 (en) | Use of antibodies for the vaccination against cancer | |
WO2001037874A3 (en) | Treatment of psoriasis by using an antibody to tnf alpha | |
IT1307864B1 (it) | Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di | |
EP1808179A3 (de) | Verwendung von HSP20 zur Förderung der Wundheilung und/oder zur Reduzierung der Narbenbildung | |
ATE444762T1 (de) | Therapeutische zusammenseztungen zur toleranzinduktion | |
DK1313850T3 (da) | Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer | |
ATE537257T1 (de) | Mit iga-nephropathie assoziierte dns | |
ATE329898T1 (de) | Kombinationspräparat zur therapie von immunologischen erkrankungen | |
WO2001079434A3 (fr) | Nouveau polypeptide, signal peptidase humaine 10, et polynucleotide codant pour ce polypeptide | |
WO2001075016A3 (fr) | Nouveau polypeptide, tyrosinase humaine 16, et polynucleotide codant pour ce polypeptide | |
WO2001075036A3 (fr) | Nouveau polypeptide, immunophiline humaine 14, et polynucleotide codant pour ce polypeptide | |
WO2001075010A3 (fr) | Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide | |
WO2001079431A3 (fr) | Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide | |
WO2001075006A3 (fr) | Nouveau polypeptide, chaîne légere de protéine réseau 37, et polynucléotide codant pour ce polypeptide | |
WO2001075051A3 (fr) | Nouveau polypeptide, proteine humaine 17 stag3 (antigene stromal), et polynucleotide codant pour ce polypeptide | |
ITPT20020011A0 (it) | Sistema ottico per la misura dell'usurae dei parametri geometrici della linea di contatto in ambito ferroviario. |